Evidence Table 111. KQ 3—Continuous Serum potassium

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Budoff 200410  Parallel | At high risk for CHD | Statins + aspirin | 10-40 | Garlic | 9 | Unit: mg/dl | NR | Mean: -0.01  SD: 1.15 | P:0.7464 | N/A | Medium | |
| Placebo | 10 | NR | Mean: -0.15  SD: 0.64 |
| Wirell 199467  Crossover | Unclear | metoprolol, atenolol, pindolol & propanolol | NR | Magnesium | 39 | NR  mmol/L | Mean: 4  SD: 0.3 | NR | P: 0.045 Crude difference | N/A | | Medium |
| Placebo | 39 | Mean: 3.9  SD: 0.3 | NR |